1561958-56-2

Upstream product

• 1403387-35-8 2-(3-(tert-butyl)-5-(1-methylcyclopropyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1403387-37-0 1-bromo-3-(tert-butyl)-5-(1-methylcyclopropyl)benzene 
• 1403387-36-9 1-bromo-3-(tert-butyl)-5-(prop-1-en-2-yl)benzene 
• 129316-09-2 1,3-dibromo-5-t-butylbenzene 
• 38041-19-9 4-aminotetrahydropyran 
• 1561964-95-1 5-(3-(tert-butyl)-5-(1-methylcyclopropyl)phenyl)-4-(cyclohexylmethyl)-1H-pyrrole-2-carboxylic acid 
• 1561964-93-9 methyl 5-(3-(tert-butyl)-5-(1-methylcyclopropyl)phenyl)-4-(cyclohexylmethyl)-1H-pyrrole-2-carboxylate 
• 1561964-90-6 methyl 5-bromo-4-(cyclohexylmethyl)-1H-pyrrole-2-carboxylate 
• 1561964-88-2 methyl 4-(cyclohexylmethyl)-1H-pyrrole-2-carboxylate 
• 40611-79-8 methyl 4-formyl-1H-pyrrole-2-carboxylate 
• 931-51-1 cyclohexylmagnesiumchloride 
• 1561964-86-0 methyl 4-(cyclohexyl(hydroxy)methyl)-1H-pyrrole-2-carboxylate 

Relevant academic research and scientific papers

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.